StockData
ELI LILLY & Co logo

ELI LILLY & Co (LLY) operating KPIs

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)

Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%

Eli Lilly neuroscience — Outside U.S. revenue ($M) ($M)

Form 10-Q / 10-K Note 2

QuarterlyAnnual
Latest, Q2 2026
104
Period ended Jun 30, 2026
Change on a year earlier
+8.3%
96 in Q2 2025
History
38 quarters
Since Q1 2017
Sources
33
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNeuroscience — Outside U.S. revenue ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026104+8.3%Form 10-Q (filed 2026-08-05) ↗
Q1 2026Mar 31, 202689+7.2%Form 10-Q (filed 2026-04-30) ↗
Q4 2025Dec 31, 2025139-18.2%Form 10-K (filed 2026-02-12) ↗
Q3 2025Sep 30, 202576.1-49.4%Form 10-Q (filed 2025-10-30) ↗
Q2 2025Jun 30, 202596-35.0%Form 10-Q (filed 2026-08-05) ↗
Q1 2025Mar 31, 202583-63.3%Form 10-Q (filed 2026-04-30) ↗
Q4 2024Dec 31, 2024170-5.6%Form 10-K (filed 2026-02-12) ↗
Q3 2024Sep 30, 2024151-90.4%Form 10-Q (filed 2025-10-30) ↗
Q2 2024Jun 30, 2024148-34.8%Form 10-Q (filed 2025-08-07) ↗
Q1 2024Mar 31, 2024226+4.6%Form 10-Q (filed 2025-05-01) ↗
Q4 2023Dec 31, 2023180-17.0%Form 10-K (filed 2026-02-12) ↗
Q3 2023Sep 30, 20231,561+586.3%Form 10-Q (filed 2024-10-30) ↗
Q2 2023Jun 30, 2023226-7.7%Form 10-Q (filed 2024-08-08) ↗
Q1 2023Mar 31, 2023216-11.6%Form 10-Q (filed 2024-04-30) ↗
Q4 2022Dec 31, 2022217-29.8%Form 10-K (filed 2025-02-19) ↗
Q3 2022Sep 30, 2022227-25.6%Form 10-Q (filed 2023-11-02) ↗

Cite this data

StockData. (2026). Eli Lilly Neuroscience — Outside U.S. revenue ($M) ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/ta_neuroscience_nonus

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.